Association between sweetened soft drinks and mortality — large European study

Organisation: Position: Deadline Date: Location:

The consumption of sugar-sweetened and artificially sweetened soft drinks was positively associated with all-cause deaths in a large European cohort over more than 16 years.

The study, coordinated by researchers from the International Agency for Research on Cancer (IARC), examined the association between total, sugar-sweetened, and artificially sweetened soft drink consumption and subsequent total and cause-specific mortality.

The study included data from more than 450,000 people in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, with an average follow-up period of more than 16 years. Compared with participants who drank less than one glass of sugar-sweetened or artificially sweetened soft drinks per month, participants who drank two or more glasses of these drinks per day had a higher risk of all-cause mortality.

In addition, consumption of two or more glasses of artificially sweetened soft drinks per day was found to be positively associated with deaths from circulatory diseases, and consumption of one or more glasses of sugar-sweetened soft drinks per day was found to be positively associated with deaths from digestive diseases.

Abstract
Importance: Soft drinks are frequently consumed, but whether this consumption is associated with mortality risk is unknown and has been understudied in European populations to date.
Objective: To examine the association between total, sugar-sweetened, and artificially sweetened soft drink consumption and subsequent total and cause-specific mortality.
Design, Setting, and Participants: This population-based cohort study involved participants (n = 451 743 of the full cohort) in the European Prospective Investigation into Cancer and Nutrition (EPIC), an ongoing, large multinational cohort of people from 10 European countries (Denmark, France, Germany, Greece, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom), with participants recruited between January 1, 1992, and December 31, 2000. Excluded participants were those who reported cancer, heart disease, stroke, or diabetes at baseline; those with implausible dietary intake data; and those with missing soft drink consumption or follow-up information. Data analyses were performed from February 1, 2018, to October 1, 2018.
Exposure: Consumption of total, sugar-sweetened, and artificially sweetened soft drinks.
Main Outcomes and Measures: Total mortality and cause-specific mortality. Hazard ratios (HRs) and 95% CIs were estimated using multivariable Cox proportional hazards regression models adjusted for other mortality risk factors.
Results: In total, 521 330 individuals were enrolled. Of this total, 451 743 (86.7%) were included in the study, with a mean (SD) age of 50.8 (9.8) years and with 321 081 women (71.1%). During a mean (range) follow-up of 16.4 (11.1 in Greece to 19.2 in France) years, 41 693 deaths occurred. Higher all-cause mortality was found among participants who consumed 2 or more glasses per day (vs consumers of <1 glass per month) of total soft drinks (hazard ratio [HR], 1.17; 95% CI, 1.11-1.22; P < .001), sugar-sweetened soft drinks (HR, 1.08; 95% CI, 1.01-1.16; P = .004), and artificially sweetened soft drinks (HR, 1.26; 95% CI, 1.16-1.35; P < .001). Positive associations were also observed between artificially sweetened soft drinks and deaths from circulatory diseases (≥2 glasses per day vs <1 glass per month; HR, 1.52; 95% CI, 1.30-1.78; P < .001) and between sugar-sweetened soft drinks and deaths from digestive diseases (≥1 glass per day vs <1 glass per month; HR, 1.59; 95% CI, 1.24-2.05; P < .001).
Conclusions and Relevance: This study found that consumption of total, sugar-sweetened, and artificially sweetened soft drinks was positively associated with all-cause deaths in this large European cohort; the results are supportive of public health campaigns aimed at limiting the consumption of soft drinks.

Authors
Amy Mullee; Dora Romaguera; Jonathan Pearson-Stuttard; Vivian Viallon; Magdalena Stepien; Heinz Freisling; Guy Fagherazzi; Francesca-Romana Mancini; Marie-Christine Boutron-Ruault; Tilman Kühn; Rudolf Kaaks; Heiner Boeing; Krasimira Aleksandrova; Anne Tjønneland; Jytte Halkjær; Kim Overvad; Elisabete Weiderpass; Guri Skeie; Christine L Parr; J Ramón Quirós; Antonio Agudo; Maria-Jose Sánchez; Pilar Amiano;Lluís Cirera; Eva Ardanaz; Kay-Tee Khaw; Tammy YY Tong; Julie A Schmidt; Antonia Trichopoulou; Georgia Martimianaki; Anna Karakatsani; Domenico Palli;Claudia Agnoli; Rosario Tumino; Carlotta Sacerdote; Salvatore Panico; Bas Bueno-de-Mesquita; WM Monique Verschuren; Jolanda MA Boer; Roel Vermeulen; Stina Ramne; Emily Sonestedt; Bethany van Guelpen; Pernilla Lif Holgersson; Konstantinos K Tsilidis; Alicia K Heath; David Muller; Elio Riboli; Marc J Gunter; Neil Murphy

International Agency for Research on Cancer material
JAMA Internal Medicine abstract


Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.